By drastically enhancing the effectiveness of CD19 CAR T-cell therapies against lymphoma cells with low or no CD19 antigen expression, Aleta is set to increase B-cell cancer cure rates significantly.

Recently, we reported that deep B cell depletion using a single infusion with autologous CD19 chimeric antigen receptor (CAR) T cells induced drug-free clinical remission in severe SLE patients with ...

Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for ...